Table 1.

GST-MDA-7 causes a caspase-9-dependent induction of primary human glioma cell death

Treatment: caspase inhibitor	GBM5 GST	GBM5 GST-MDA-7	GBM6 GST	GBMG GST-MDA-7	GBM12 GST	GBM12 GST-MDA-7
Vehicle	2.2 ± 0.6	34.0 ± 2.1	4.4 ± 0.6	45.2 ± 2.3	2.1 ± 0.8	20.3 ± 0.8
z-VAD	2.9 ± 1.0	7.7 ± 0.6*	6.4 ± 0.4	11.7 ± 1.5*	4.0 ± 1.2	9.1 ± 1.5*
IETD	3.4 ± 1.0	34.4 ± 2.9	4.8 ± 0.2	45.0 ± 7.2	3.5 ± 1.4	20.7 ± 2.7
LEHD	3.6 ± 7.5	8.9 ± 1.7*	3.3 ± 2.3	12.0 ± 1.5*	4.7 ± 1.8	11.0 ± 0.6*

NOTE: Primary human glioma cells (GBM5, GBM6, and GBM12) were treated 24 h after plating with vehicle (DMSO), a pan-caspase inhibitor (z-VAD), a caspase-8 specific inhibitor (IETD), or a caspase-9 specific inhibitor (LEHD; all at 50 μmol/L) followed 30 min later by treatment of cells with 20 nmol/L GST-MDA-7 or GST. Cell viability was determined 96 h after GST-MDA-7 treatment by trypan blue exclusion assays in triplicate using a hemacytometer (±SE; n = 5).

^*P < 0.05, lower amount of cell killing than vehicle-treated cells.